Novartis nixes another $600M buyout deal for Gamida Cell

John Carroll Novartis won't be pulling the trigger on a $ 600 million buyout deal for Israel's Gamida Cell after all. Elbit Imaging, the majority owner of a minority stakeholder ...

Oxford BioMedica takes out $50M loan to service Novartis CAR-T alliance

Nick Paul Taylor Oxford BioMedica has secured a $ 50 million (€45 million) loan, half of which it will take out immediately to expand its laboratory and manufacturing facilities. ...

J&J, Novartis lead pharma companies by market cap

Carly Helfand Which Big Pharma companies have the biggest market caps in the industry? The Motley Fool has a breakdown of the top 10, but we'll give you a hint: The list ...

Cost watchdogs back Novartis’ Xolair for big new market in chronic hives

Tracy Staton England's cost-effectiveness watchdogs have changed their mind on Xolair. The National Institute for Health and Care Excellence decided to back the Novartis asthma ...

Novartis CEO eyes more cost cuts to satisfy margin demands

Tracy Staton Novartis execs are rolling up their sleeves for another round of cost cuts. "Very significant" cost cuts, CEO Joe Jimenez tells the Financial Times, partly from ...

Pfizer, Novartis: CDC’s MenB nod is too narrow

Carly Helfand Pfizer and Novartis have snagged a nod from the CDC's Advisory Committee on Immunization Practices (ACIP) for their recently approved meningitis B vaccines. ...

Novartis looks to squelch neuro worries over its would-be cardio blockbuster

Damian Garde Novartis, at work on a cardio drug widely expected to bring in billions of dollars once approved, is working to tamp down concerns that the oral treatment could increase ...

Deal-weighing Pharmacyclics could draw $18B from J&J, Novartis: Bloomberg

Carly Helfand So far, the 2014 pharma deal blitz has continued right on into 2015. And cancer drugmaker Pharmacyclics could be the next company to keep it going. FiercePharma News

Novartis bags a surprise approval for the blood cancer-treating panobinostat

Damian Garde Going against the advice of its independent experts, the FDA approved Novartis' new blood cancer drug for patients with particularly deadly forms of multiple myeloma, ...

Novartis makes Israel a priority, U.K. dreams up Alzheimer’s R&D hub, Shire defends tax model

Nick Paul Taylor In this week's EuroBiotech Report, Novartis is getting deeper into the Israeli biotech scene, tasking BioLineRx with keeping tabs on local startups after realizing ...

Novartis makes concerted push into Israeli biotech startup scene

Nick Paul Taylor Over the past year, Novartis has struck a pair of deals in Israel, snagging an option to buy Gamida Cell and a stake in BioLineRx. FierceBiotech News

Investigators link Novartis’ would-be cardio blockbuster to Alzheimer’s risk

John Carroll Novartis' heart failure med LCZ696 has singlehandedly saved the pharma giant's cardio drug development strategy from the embarrassing setback triggered by serelaxin's ...
Page 3 of 1412345...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS